EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry

Renate B Schnabel iD, Pietro Ameri iD, Jolanta M Siller-Matula iD, Igor Diemberger iD, Marianne Gwechenberger, Ladislav Pecen iD, Marius Constantin Manu, José Souza, Raffaele De Caterina iD, Paulus Kirchhof iD

Europace · 2023

DOI: 10.1093/europace/euad280 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Europace, 2023. Verfasst von Renate B Schnabel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Clinic Hamburg-Eppendorf, University Heart and Vascular Centre Hamburg-Eppendorf, Buildung O50, Martinistrasse 5…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Stroke, Ischemic Attack, Transient, Brain Ischemia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council, Daiichi Sankyo Deutschland GmbH, Horizon 2020.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Heart failure (HF) is a risk factor for major adverse events in atrial fibrillation (AF). Whether this risk persists on non-vitamin K antagonist oral anticoagulants (NOACs) and varies according to left ventricular ejection fraction (LVEF) is debated. Methods and results We investigated the relation of HF in the ETNA-AF-Europe registry, a prospective, multicentre, observational study with an overall 4-year follow-up of edoxaban-treated AF patients. We report 2-year follow-up for ischaemic stroke/transient ischaemic attack (TIA)/systemic embolic events (SEE), major bleeding, and mortality. Of the 13 133 patients, 1854 (14.1%) had HF. Left ventricular ejection fraction was available for 82.4% of HF patients and was <40% in 671 (43.9%) and ≥40% in 857 (56.1%). Patients with HF were older, more often men, and had more comorbidities. Annualized event rates (AnERs) of any stroke/SEE were 0.86%/year and 0.67%/year in patients with and without HF. Compared with patients without HF, those with HF also had higher AnERs for major bleeding (1.73%/year vs. 0.86%/year) and all-cause death (8.30%/year vs. 3.17%/year). Multivariate Cox proportional models confirmed HF as a significant predictor of major bleeding [hazard ratio (HR) 1.65, 95% confidence interval (CI): 1.20–2.26] and all-cause death [HF with LVEF <40% (HR 2.42, 95% CI: 1.95–3.00) and HF with LVEF ≥40% (HR 1.80, 95% CI: 1.45–2.23)] but not of ischaemic stroke/TIA/SEE.

Conclusion

Anticoagulated patients with HF at baseline featured higher rates of major bleeding and all-cause death, requiring optimized management and novel preventive strategies. NOAC treatment was similarly effective in reducing risk of ischaemic events in patients with or without concomitant HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationStrokeIschemic Attack, TransientBrain IschemiaEmbolismIschemic StrokeHeart FailureMaleHumansAnticoagulantsProspective StudiesStroke VolumeAdministration, OralVentricular Function, LeftHemorrhageRegistries

Stichwörter der Autor:innen

Atrial fibrillationEdoxabanHeart failureLeft ventricular ejection fractionNon-vitamin K antagonist oral anticoagulantRegistry

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Cardiology, University Clinic Hamburg-Eppendorf, University Heart and Vascular Centre Hamburg-Eppendorf, Buildung O50, Martinistrasse 52, 20246 Hamburg, Germany.
  • DZHK (German Centre for Cardiovascular Research), partner site Hamburg/Kiel/Luebeck, Potsdamer Str, 5810785 Berlin, Germany.
  • Department of Internal Medicine, University of Genova, Genova, Italy.
  • Cardiac, Thoracic and Vascular Department, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
  • Department of Cardiology, Medical University of Vienna, Vienna, Austria.
  • Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy.

ORCID-Profile: Renate B Schnabel, Pietro Ameri, Jolanta M Siller-Matula, Igor Diemberger, Ladislav Pecen, Raffaele De Caterina, Paulus Kirchhof

Förderung

  • European Research Council
  • Daiichi Sankyo Deutschland GmbH
  • Horizon 2020
  • German Center for Cardiovascular Research
  • German Ministry of Research and Education

Zitieren

APA

Schnabel, R. B., Ameri, P., Siller-Matula, J. M., Diemberger, I., Gwechenberger, M., Pecen, L., Manu, M. C., Souza, J., De Caterina, R., & Kirchhof, P. (2023). Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry. Europace. https://doi.org/10.1093/europace/euad280

Vancouver

Schnabel RB, Ameri P, Siller-Matula JM, Diemberger I, Gwechenberger M, Pecen L, et al. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry. Europace. 2023. doi:10.1093/europace/euad280

BibTeX
@article{Schnabel2023,
  author = {Schnabel, Renate B and Ameri, Pietro and Siller-Matula, Jolanta M and Diemberger, Igor and Gwechenberger, Marianne and Pecen, Ladislav and Manu, Marius Constantin and Souza, José and De Caterina, Raffaele and Kirchhof, Paulus},
  title = {Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry},
  journal = {Europace},
  year = {2023},
  doi = {10.1093/europace/euad280}
}
Kostenlos starten →